(C) Clinipace 2015 - Jeffrey WilliamsClinipace Pays High Sum for Accovion

March 2015. Following the acquisition of PFC Pharma Focus Clinipace founder Jeffrey Williams invested another high sum to have freedom to operate. He intends to speed up expansion in order to increase the profitability of Clinipace Europe. Read about teh role of Accovion and learn the amount of equity in buying out shareholders.


If you like to read this article, you can purchase it now

Please notice, when purchasing articles you agree to B2Bioworld's Terms and Conditions

Read Now - Please select your license (Prices incl. 7% VAT)

Article free of advertisement - 1 page

Full Company License enquire here

Back to section

Related Editorial Articles

Make or Break Drug Discovery and Biopharma of Merck Life Science

Transition Cancer Research Translation
Christof von Kalle, Head of Germany’s National Center for Tumor Diseases on transitions in translational cancer research

Patient-centered Precision Care
Michael Christman, President of Coriell Institute about turning research on human genotyping into healthcare routine

The Myriad Way
Peter D Meldrum, past CEO of the genetics company about battles on patents, cancer chips, and competitors in commercial academia

Custom Sequencing Markets
Worldwide evolution of the market and upcoming business opportunities

Metrics for Disease, Health, and Wellness
A systems look at DNA sequencing for personalized medicine by Leroy Hood, President Institute for Systems Biology, Seattle

Network intelligence for Lundbeck’s new drugs

Martin Schröder appointed CEO of Accovion, Co-founder Wilhelm Horn quits the company